The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low‐resource setting

Sy, Stephen; Jj, Kim

doi:10.1111/1471-0528.13503

Cited by 10 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some of them supported the need to extend vaccination to school-age boys, others did not if the vaccination of women was extended to up to 26 years. Other studies underlined the uselessness of vaccination in heterosexual men and boys if the vaccination in women was 75% or more (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26).…”

Section: Results Of the Individual Studiesmentioning

confidence: 99%

See 1 more Smart Citation

HPV vaccine for men: Where to? (Review)

et al. 2021

View full text Add to dashboard Cite

Human papillomavirus (HPV) is one of the most widespread human pathogens. For a long time, it was treated as an opportunistic infection, but it is in actuality one of the most dangerous carcinogens. It is responsible for numerous malignancies: Cervical, penile, oropharyngeal, vaginal, vulvar and some anal neoplasia. The need for a long-term solution was evident and thus HPV vaccines were proven to be a viable solution. Women and men who have sex with men, and young men are included in the vaccination template. A thorough review using PubMed and other databases that included articles on vaccine templates and targeted male patients was carried out. After review of all of the studies conducted on this subject, there is a clear benefit for HPV vaccination for men. Yet, even with the introduction of a national vaccine program for HPV for women and girls in most developed countries, regarding the male vaccine program, few countries have established a national program. Still, a gender-neutral vaccine remains a controversial issue. It is important to monitor the impact of HPV vaccine in men and the benefits that occur, to inform and spread the results in order to implement this vaccine program worldwide. Any monitoring plan regarding the HPV vaccination must include HPV prevalence, anogenital warts, and anal cancer. The largest impact regarding the range of this type of vaccine is the surveillance of the specific targeted population. HPV vaccine is a very efficient immunization method. Women are obviously the first target, but there are still many contradictions regarding men. Most of the reasons reside in the cost-efficiency aspect, but there is still great debate regarding the most efficient vaccine in the male population. Contents 1. Introduction 2. Data collection process 3. Study characteristics 4. Results of the individual studies 5. Synthesis of the results 6. Acceptance of the HPV vaccine 7. Summary of the evidence 8. Contraindication for the HPV vaccine? 9. Conclusions

show abstract

Section: Results Of the Individual Studiesmentioning

confidence: 99%

“…They stressed the need for vaccination for MSM and the need to attain higher rates of vaccination in this population. Unfortunately, the cost of the vaccine is a milestone, and thus are the number of doses and the length of coverage of the vaccine (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26).…”

Section: Results Of the Individual Studiesmentioning

confidence: 99%

HPV vaccine for men: Where to? (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…prices available to Gavi, the Vaccine Alliance and the Pan American Health Organisation Revolving Fund) [27]. The opportunity to pair vaccination with some screening in adulthood has also been shown to be promising in some countries [18,[80], [81], [82], [83], [84], [85], [86], [87], [88], [89], [90], [91], [92], [93], [94], [95]]. Screening has also been found to be cost-effective in several analyses of HIV-infected women and populations with a high burden of HIV [[96], [97], [98]].…”

Section: Domain 5 Additional Issues In Reporting Modelled Evaluationmentioning

confidence: 99%

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Canfell

Kim²,

Kulasingam

et al. 2019

Papillomavirus Research

View full text Add to dashboard Cite

Intense research activity in HPV modelling over this decade has prompted the development of additional guidelines to those for general modelling. A specific framework is required to address different policy questions and unique complexities of HPV modelling. HPV-FRAME is an initiative to develop a consensus statement and quality-based framework for epidemiologic and economic HPV models. Its development involved an established process. Reporting standards have been structured according to seven domains reflecting distinct policy questions in HPV and cancer prevention and categorised by relevance to a population or evaluation. Population-relevant domains are: 1) HPV vaccination in pre-adolescent and young adolescent individuals; 2) HPV vaccination in older individuals; 3) targeted vaccination in men who have sex with men; 4) considerations for individuals living with HIV and 5) considerations for low- and middle-income countries. Additional considerations applicable to specific evaluations are: 6) cervical screening or integrated cervical screening and HPV vaccination approaches and 7) alternative vaccine types and alternative dosing schedules. HPV-FRAME aims to promote the development of models in accordance with an explicit framework, to better enable target audiences to understand a model's strength and weaknesses in relation to a specific policy question and ultimately improve the model's contribution to informed decision-making.

show abstract

“…Of 26 selected studies 12,21-44 on gender-neutral vaccination (three in LMICs and 23 in HICs), two studies examined 2vHPV vaccine, 20 on 4vHPV, and four on 9vHPV vaccines. Sixteen studies [22][23][24][25]27,[36][37][38][39][40][41][42][43][44][45][46] demonstrated that HPV vaccination for heterosexual men with an existing female program was costeffective (ICER = $19,600-52,800/QALY gained in HICs and $49-5,860/QALY gained in LMICs, Table S1) with respect to their respective cost-effectiveness thresholds (Figure 2a).…”

Section: Cost-effectiveness Of Hpv Vaccination For Heterosexual Menmentioning

confidence: 99%

Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness

Soe

Ong

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Background: Human papillomavirus (HPV) vaccination for young women up to age 26 is highly costeffective and has been implemented in 65 countries globally. We investigate the cost-effectiveness for HPV vaccination program in older women (age > 26 years), heterosexual men and men who have sex with men (MSM). Method: A targeted literature review was conducted on PubMed for publications between January 2000 and January 2017 according to the PRISMA guidelines. We included English-language articles that reported the incremental cost-effectiveness ratio (ICER) of HPV vaccination programs for women over age 26, heterosexual men, and MSM and identified the underlying factors for its cost-effectiveness. Results: We included 36 relevant articles (six, 26 and four in older women, heterosexual men and MSM, respectively) from 17 countries (12 high-income (HICs) and five low-and middle-income (LMICs) countries). Most (4/6) studies in women over age 26 did not show cost-effectiveness ($65,000-192,000/QALY gained). Two showed cost-effectiveness, but only when the vaccine cost was largely subsidised and protection to non-naïve women was also considered. Sixteen of 26 studies in heterosexual men were cost-effective (ICER = $19,600-52,800/QALY gained in HICs; $49-5,860/QALY gained in LMICs). Nonavalent vaccines, a low vaccine price, fewer required doses, and a long vaccine protection period were key drivers for cost-effectiveness. In contrast, all four studies on MSM consistently reported cost-effectiveness (ICER = $15,000-$43,000/QALY gained), particularly in MSM age < 40 years and those who were HIV-positive. Countries' vaccination coverage did not significantly correlate with its per-capita Gross National Income. Conclusion: Targeted HPV vaccination for MSM should be next priority in HPV prevention after having established a solid girls vaccination programme. Vaccination for heterosexual men should be considered when 2-dose 4vHPV/9vHPV vaccines become available with a reduced price, whereas targeted vaccination for women over age 26 is unlikely to be cost-effective.

show abstract

The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low‐resource setting

Cited by 10 publications

References 24 publications

HPV vaccine for men: Where to? (Review)

HPV vaccine for men: Where to? (Review)

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness

Contact Info

Product

Resources

About